ICUCW — SeaStar Medical Holding Corp

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1831868 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 615,000 561,000 -3,791,000 -3,730,000 8,649,000 6,959,000 4,353,000
Mar 2026 495,000 449,000 -3,603,000 -3,521,000 11,263,000 9,348,000 3,948,000
Dec 2025 420,000 408,000 -3,016,000 -2,904,000 14,158,000 11,980,000 3,742,000
Sep 2025 183,000 169,000 -3,579,000 -3,472,000 15,530,000 13,763,000 4,066,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,693,000
Investing CF
—
Financing CF
$14,350,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-158,965,000
Inventory
$77,000
Receivables
$208,000
ST Investments
—
EBIT TTM
$-13,597,000
Pretax Income TTM
$-13,624,000
Interest Exp TTM
$27,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,713,000
EBITDA
—
Free Cash Flow
$-9,141,000
Enterprise Value
—
Total Cash
$6,959,000
Total Debt
$134,000
Shares Out
—
Trailing EPS
—
Book Value
$2.71
ROE
-356.9%
ROA
-102.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,234,000 -12,175,000 -12,150,000 14,158,000 3,742,000 10,416,000 -13,599,000
Dec 2024 135,000 -17,842,000 -24,830,000 4,658,000 6,841,000 -2,183,000 -16,007,000
Dec 2023 0 -14,210,000 -26,232,000 3,513,000 17,383,000 -13,870,000 -10,285,000
Dec 2022 0 -11,609,000 -12,190,000 3,038,000 23,800,000 -20,762,000 -7,794,000

TTM Snapshot

Revenues TTM
$1,713,000
NetIncome TTM
$-13,627,000
OpCashFlow TTM
—
Assets (Latest)
$8,649,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
ISRG INTUITIVE SURGICAL INC $152.10B $430.53 —
MDT Medtronic plc $130.88B $102.32 —
SYK STRYKER CORP $120.88B $317.54 —
MMM 3M CO $93.28B $180.88 —
BSX BOSTON SCIENTIFIC CORP $62.37B $43.03 —

News headlines (Yahoo Finance, 1h cache)

ICU: QUELIMMUNE® Commercial Adoption Continues; Adult AKI Study Progresses Toward 2027 Completion
2026-11-16 10:38 · Yahoo
SeaStar Medical Holding Corporation Q3 2026 Earnings Call Summary
2026-11-13 01:55 · Yahoo
SeaStar Medical Holding Corp (ICU) (Q3 2026) Earnings Call Highlights: Qualimmune Revenue Jumps ...
2026-11-12 05:06 · Yahoo
SeaStar Medical (ICU) Q3 2026 Earnings Call Transcript
2026-11-12 02:28 · Yahoo
SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-11 21:05 · Yahoo
SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026
2026-11-04 13:41 · Yahoo
FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients
2026-11-03 13:21 · Yahoo
ICU: QUELIMMUNE® Demonstrates Statistically Significant Survival Benefit in SAVE Registry Patients
2026-10-23 11:11 · Yahoo
SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI
2026-10-22 16:01 · Yahoo
SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award
2026-10-14 12:37 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.